H.C. Wainwright Thinks Aquestive Therapeutics Inc’s Stock is Going to Recover

By Austin Angelo

Aquestive Therapeutics Inc (AQSTResearch Report) received a Buy rating and a $10 price target from H.C. Wainwright analyst Ram Selvaraju today. The company’s shares closed on Thursday at $6.29, close to its 52-week low of $5.60.

Selvaraju said:

“We utilize a discounted cash flow (DCF)-based assessment to value Aquestive Therapeutics shares. Using a composite of contributions from Sympazan and Libervant sales along with APL-130277 royalties, plus the impact of legacy revenues from royalties on sales of Suboxone and Zuplenz, we derive a total risk-adjusted net present value (rNPV) of $312M. We employ a discount rate of 15% and effective tax rate of 30%. Our probability of approval for Libervant is 90%, while we utilize a 75% probability of approval for APL-130277.”

According to TipRanks.com, Selvaraju has currently no stars on a ranking scale of 0-5 stars, with an average return of -2.3% and a 31.7% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Taro Pharmaceutical Industries Ltd., Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.

Currently, the analyst consensus on Aquestive Therapeutics Inc is a Strong Buy with an average price target of $20.75, representing a 229.9% upside. In a report issued on April 16, Wedbush also reiterated a Buy rating on the stock with a $31 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $20.70 and a one-year low of $5.60. Currently, Aquestive Therapeutics Inc has an average volume of 108.6K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aquestive Therapeutics, Inc. is a specialty pharmaceutical company focused on identifying, developing, and commercializing differentiated products to address unmet medical needs. The company has a late-stage proprietary product pipeline focused on the treatment of Central nervous system (CNS) diseases, as well as orally-administered complex molecules that can be alternatives to invasively-administered standard of care therapies. Its product candidates include Libervant, Sympazan, and AQST-117 (Riluzole). Aquestive Therapeutics develops and delivers drugs via its PharmFilm® technology. The firm also collaborates with pharmaceutical partners to bring new molecules to market in differentiated and highly-marketable dosage forms. In addition to its proprietary product candidates, the company, with its partners, has a portfolio of development-stage products and commercialized products, such as Suboxone, a prescription medicine for the treatment of opioid dependence. The company was founded in January 2004 and is headquartered in Warren, NJ.